BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. Target Oncol 2017;12:571-97. [PMID: 28815409 DOI: 10.1007/s11523-017-0514-5] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Kang J, Guo Z, Zhang H, Guo R, Zhu X, Guo X. Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer. IJMS 2022;23:10382. [DOI: 10.3390/ijms231810382] [Reference Citation Analysis]
2 Sundqvist B, Kilpinen S, Böhling T, Koljonen V, Sihto H. Activation of Oncogenic and Immune-Response Pathways Is Linked to Disease-Specific Survival in Merkel Cell Carcinoma. Cancers 2022;14:3591. [DOI: 10.3390/cancers14153591] [Reference Citation Analysis]
3 Sair AT, Liu RH. Molecular regulation of phenolic compounds on IGF-1 signaling cascade in breast cancer. Food Funct 2022;13:3170-84. [PMID: 35253808 DOI: 10.1039/d1fo03283f] [Reference Citation Analysis]
4 ZeinElAbdeen YA, AbdAlSeed A, Youness RA. Decoding Insulin-Like Growth Factor Signaling Pathway From a Non-coding RNAs Perspective: A Step Towards Precision Oncology in Breast Cancer. J Mammary Gland Biol Neoplasia 2022. [PMID: 35146629 DOI: 10.1007/s10911-022-09511-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Franchini F, Palatucci G, Colao A, Ungaro P, Macchia PE, Nettore IC. Obesity and Thyroid Cancer Risk: An Update. Int J Environ Res Public Health 2022;19:1116. [PMID: 35162142 DOI: 10.3390/ijerph19031116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Kim DS, Scherer PE. Obesity, Diabetes, and Increased Cancer Progression. Diabetes Metab J 2021;45:799-812. [PMID: 34847640 DOI: 10.4093/dmj.2021.0077] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Park K, Tan DSW, Su WC, Cho BC, Kim SW, Lee KH, Wang CC, Seto T, Huang DC, Jung HH, Hsu MC, Bogenrieder T, Lin CC. Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO Clin Res Rep 2021;2:100206. [PMID: 34590052 DOI: 10.1016/j.jtocrr.2021.100206] [Reference Citation Analysis]
8 Wang H, Shan B, Duan Y, Zhu J, Jiang L, Liu Y, Zhang Y, Qi F, Niu S. Effects of Heshouwuyin on gene expression of the insulin/IGF signalling pathway in rat testis and spermatogenic cells. Pharm Biol 2020;58:1199-210. [PMID: 33264567 DOI: 10.1080/13880209.2020.1839511] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Catellani C, Ravegnini G, Sartori C, Angelini S, Street ME. GH and IGF System: The Regulatory Role of miRNAs and lncRNAs in Cancer. Front Endocrinol (Lausanne) 2021;12:701246. [PMID: 34484116 DOI: 10.3389/fendo.2021.701246] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Grega T, Vojtechova G, Gregova M, Zavoral M, Suchanek S. Pathophysiological Characteristics Linking Type 2 Diabetes Mellitus and Colorectal Neoplasia. Physiol Res 2021;70:509-22. [PMID: 34062073 DOI: 10.33549/physiolres.934631] [Reference Citation Analysis]
11 Mancarella C, Morrione A, Scotlandi K. Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options. Cells 2021;10:2075. [PMID: 34440844 DOI: 10.3390/cells10082075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Vithayathil M, Carter P, Kar S, Mason AM, Burgess S, Larsson SC. Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: A mendelian randomisation study. PLoS Med 2021;18:e1003706. [PMID: 34324486 DOI: 10.1371/journal.pmed.1003706] [Reference Citation Analysis]
13 McShane R, Arya S, Stewart AJ, Caie P, Bates M. Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma. Biochim Biophys Acta Rev Cancer 2021;:188598. [PMID: 34332022 DOI: 10.1016/j.bbcan.2021.188598] [Reference Citation Analysis]
14 Pal A, Barrett TF, Paolini R, Parikh A, Puram SV. Partial EMT in head and neck cancer biology: a spectrum instead of a switch. Oncogene 2021;40:5049-65. [PMID: 34239045 DOI: 10.1038/s41388-021-01868-5] [Reference Citation Analysis]
15 Erdem C, Lee AV, Taylor DL, Lezon TR. Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells. PLoS Comput Biol 2021;17:e1009125. [PMID: 34191793 DOI: 10.1371/journal.pcbi.1009125] [Reference Citation Analysis]
16 Weidle UH, Birzele F, Brinkmann U, Auslaender S. Gastric Cancer: Identification of microRNAs Inhibiting Druggable Targets and Mediating Efficacy in Preclinical In Vivo Models. Cancer Genomics Proteomics 2021;18:497-514. [PMID: 34183383 DOI: 10.21873/cgp.20275] [Reference Citation Analysis]
17 Heckl SM, Mau F, Senftleben A, Daunke T, Beckinger S, Abdullazade S, Schreiber S, Röcken C, Sebens S, Schäfer H. Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control. Med Sci (Basel) 2021;9:48. [PMID: 34202040 DOI: 10.3390/medsci9030048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Liu Y, Nelson MV, Bailey C, Zhang P, Zheng P, Dome JS, Liu Y, Wang Y. Targeting the HIF-1α-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor. Oncogene 2021;40:4809-19. [PMID: 34155347 DOI: 10.1038/s41388-021-01907-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Kalya M, Kel A, Wlochowitz D, Wingender E, Beißbarth T. IGFBP2 Is a Potential Master Regulator Driving the Dysregulated Gene Network Responsible for Short Survival in Glioblastoma Multiforme. Front Genet 2021;12:670240. [PMID: 34211498 DOI: 10.3389/fgene.2021.670240] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tzanakakis GN, Giatagana EM, Berdiaki A, Spyridaki I, Hida K, Neagu M, Tsatsakis AM, Nikitovic D. The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis. Cancers (Basel) 2021;13:2478. [PMID: 34069554 DOI: 10.3390/cancers13102478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Oliveres H, Pesántez D, Maurel J. Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients. Int J Mol Sci 2021;22:5019. [PMID: 34065119 DOI: 10.3390/ijms22095019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
22 Mills JV, Osher E, Rieunier G, Mills IG, Macaulay VM. IGF-1R nuclear import and recruitment to chromatin involves both alpha and beta subunits. Discov Oncol 2021;12:13. [PMID: 33969359 DOI: 10.1007/s12672-021-00407-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Rubinstein MM, Brown KA, Iyengar NM. Targeting obesity-related dysfunction in hormonally driven cancers. Br J Cancer 2021;125:495-509. [PMID: 33911195 DOI: 10.1038/s41416-021-01393-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Arias-Pinilla GA, Modjtahedi H. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers (Basel) 2021;13:1781. [PMID: 33917882 DOI: 10.3390/cancers13081781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Adeshakin FO, Adeshakin AO, Afolabi LO, Yan D, Zhang G, Wan X. Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming. Front Oncol 2021;11:626577. [PMID: 33854965 DOI: 10.3389/fonc.2021.626577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Yang J, Huang H, Xiao D, Duan Y, Zheng Y, Chen Z. Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells. Int J Oncol 2021;58:15. [PMID: 33760171 DOI: 10.3892/ijo.2021.5195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Dvorská D, Braný D, Ňachajová M, Halašová E, Danková Z. Breast Cancer and the Other Non-Coding RNAs. Int J Mol Sci 2021;22:3280. [PMID: 33807045 DOI: 10.3390/ijms22063280] [Reference Citation Analysis]
28 Bleach R, Sherlock M, O'Reilly MW, McIlroy M. Growth Hormone/Insulin Growth Factor Axis in Sex Steroid Associated Disorders and Related Cancers. Front Cell Dev Biol 2021;9:630503. [PMID: 33816477 DOI: 10.3389/fcell.2021.630503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Dayi T, Öniz A. RE-VISITED; ARE FOODS FRIEND OR FOE FOR CANCER? Journal of Basic and Clinical Health Sciences. [DOI: 10.30621/jbachs.854439] [Reference Citation Analysis]
30 Roessner A, Lohmann C, Jechorek D. Translational cell biology of highly malignant osteosarcoma. Pathol Int 2021;71:291-303. [PMID: 33631032 DOI: 10.1111/pin.13080] [Reference Citation Analysis]
31 Tilak M, Holborn J, New LA, Lalonde J, Jones N. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme. Int J Mol Sci 2021;22:1831. [PMID: 33673213 DOI: 10.3390/ijms22041831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Beltrán Hernández I, Kromhout JZ, Teske E, Hennink WE, van Nimwegen SA, Oliveira S. Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other? Theranostics 2021;11:3882-97. [PMID: 33664868 DOI: 10.7150/thno.55760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Bailes J, Soloviev M. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules 2021;11:217. [PMID: 33557137 DOI: 10.3390/biom11020217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Tirrò E, Massimino M, Romano C, Martorana F, Pennisi MS, Stella S, Pavone G, Di Gregorio S, Puma A, Tomarchio C, Vitale SR, Manzella L, Vigneri P. Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma. Front Oncol 2020;10:612385. [PMID: 33604294 DOI: 10.3389/fonc.2020.612385] [Reference Citation Analysis]
35 Rieger L, O'Connor R. Controlled Signaling-Insulin-Like Growth Factor Receptor Endocytosis and Presence at Intracellular Compartments. Front Endocrinol (Lausanne) 2020;11:620013. [PMID: 33584548 DOI: 10.3389/fendo.2020.620013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
36 Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS, Morales S, Pérez-Fidalgo JA, Adamson D, Gonçalves A, Prat A, Jerusalem G, Schlieker L, Espadero RM, Bogenrieder T, Huang DC, Crown J, Cortés J. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast Cancer Res 2021;23:8. [PMID: 33451345 DOI: 10.1186/s13058-020-01382-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lee HJ, Pham PC, Pei H, Lim B, Hyun SY, Baek B, Kim B, Kim Y, Kim MH, Kang NW, Min HY, Kim DD, Lee J, Lee HY. Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor. Theranostics 2021;11:1918-36. [PMID: 33408789 DOI: 10.7150/thno.48865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Han YY, Yan Q, Chen W, Forno E, Celedón JC. Serum insulin-like growth factor-1, asthma, and lung function among British adults. Ann Allergy Asthma Immunol 2021;126:284-291.e2. [PMID: 33316372 DOI: 10.1016/j.anai.2020.12.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 de Groot S, Röttgering B, Gelderblom H, Pijl H, Szuhai K, Kroep JR. Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma. Cancers (Basel) 2020;12:E3568. [PMID: 33260481 DOI: 10.3390/cancers12123568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Costa-Silva DR, Barros-Oliveira MDC, Alves-Ribeiro FA, Campos-Verdes LC, Nery Junior EJ, Vieira-Valença SF, Vasconcelos-Valença RJ, Soares VM, Pinho-Sobral AL, Sousa EB, Lopes-Costa PV, Dos Santos AR, Viana JL, Cardoso AC, Luz-Borges VM, Pereira RO, Tavares CB, Silva VC, Rodrigues-Junior DM, Gebrim LH, da Silva BB. Assessment of IGF-1 expression in the peripheral blood of women with recurrent breast cancer. Medicine (Baltimore) 2020;99:e22890. [PMID: 33120836 DOI: 10.1097/MD.0000000000022890] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Powell MJ, Dufault SM, Gunderson EP, Benz CC. Cancer and Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy Carrying a Common IGF1R Variant. Mayo Clin Proc 2020;95:2684-96. [PMID: 33168159 DOI: 10.1016/j.mayocp.2020.03.037] [Reference Citation Analysis]
42 Kurimchak AM, Kumar V, Herrera-Montávez C, Johnson KJ, Srivastava N, Davarajan K, Peri S, Cai KQ, Mantia-Smaldone GM, Duncan JS. Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target. Mol Cell Proteomics 2020;19:2068-90. [PMID: 32994315 DOI: 10.1074/mcp.RA120.002012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Kasprzak A, Szaflarski W. Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors. Int J Mol Sci 2020;21:E6995. [PMID: 32977489 DOI: 10.3390/ijms21196995] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nat Commun 2020;11:4607. [PMID: 32929081 DOI: 10.1038/s41467-020-18442-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
45 Bano N, Hossain MM, Bhat AQ, Ayaz MO, Kumari M, Sandhu P, Akhter Y, Dar MJ. Analyzing structural differences between insulin receptor (IR) and IGF1R for designing small molecule allosteric inhibitors of IGF1R as novel anti-cancer agents. Growth Horm IGF Res 2020;55:101343. [PMID: 32877816 DOI: 10.1016/j.ghir.2020.101343] [Reference Citation Analysis]
46 Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, Hashem AM. Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Front Immunol 2020;11:1986. [PMID: 32983137 DOI: 10.3389/fimmu.2020.01986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
47 Hermanowicz JM, Kwiatkowska I, Pawlak D. Important players in carcinogenesis as potential targets in cancer therapy: an update. Oncotarget 2020;11:3078-101. [PMID: 32850012 DOI: 10.18632/oncotarget.27689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Sarfstein R, Yeheskel A, Sinai-Livne T, Pasmanik-Chor M, Werner H. Systems Analysis of Insulin and IGF1 Receptors Networks in Breast Cancer Cells Identifies Commonalities and Divergences in Expression Patterns. Front Endocrinol (Lausanne) 2020;11:435. [PMID: 32733384 DOI: 10.3389/fendo.2020.00435] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Guo F, Zhu X, Zhao Q, Huang Q. miR‑589‑3p sponged by the lncRNA TINCR inhibits the proliferation, migration and invasion and promotes the apoptosis of breast cancer cells by suppressing the Akt pathway via IGF1R. Int J Mol Med 2020;46:989-1002. [PMID: 32705168 DOI: 10.3892/ijmm.2020.4666] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
50 Abdellateif MS, Shaarawy S, Elesawy YF, Mansour M, Tharwat E, Ibrahim NH, Eissa MS. The Role of Vitamin D, Platelet-Derived Growth Factor and Insulin-Like Growth Factor 1 in the Progression of Thyroid Diseases. Asian Pac J Cancer Prev 2020;21:2083-9. [PMID: 32711436 DOI: 10.31557/APJCP.2020.21.7.2083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 De Lima L, Sürme MB, Gessi M, Mastronuzzi A, Miele E, Tamburrini G, Massimi L. Central nervous system high-grade neuroepithelial tumor with BCOR alteration (CNS HGNET-BCOR)—case-based reviews. Childs Nerv Syst 2020;36:1589-99. [DOI: 10.1007/s00381-020-04692-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Yang HY, Wu CY, Powell JD, Lu KL. Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective. Int J Mol Sci 2020;21:E4030. [PMID: 32512898 DOI: 10.3390/ijms21114030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Zhao C, Zeng C, Ye S, Dai X, He Q, Yang B, Zhu H. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer. Acta Pharm Sin B 2020;10:947-60. [PMID: 32642404 DOI: 10.1016/j.apsb.2019.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
54 Sinai-Livne T, Pasmanik-Chor M, Cohen Z, Tsarfaty I, Werner H, Berger R. Proteomic analysis of combined IGF1 receptor targeted therapy and chemotherapy identifies signatures associated with survival in breast cancer patients. Oncotarget 2020;11:1515-30. [PMID: 32391121 DOI: 10.18632/oncotarget.27566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Roessner A, Schoeder V, Smolle M, Haybäck J. [Osteoid-forming bone tumors : Morphology and current translational cell biology]. Pathologe 2020;41:123-33. [PMID: 32078700 DOI: 10.1007/s00292-020-00763-2] [Reference Citation Analysis]
56 de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer 2020;122:1324-32. [PMID: 32161368 DOI: 10.1038/s41416-020-0774-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
57 Krieger CC, Neumann S, Gershengorn MC. TSH/IGF1 receptor crosstalk: Mechanism and clinical implications. Pharmacol Ther 2020;209:107502. [PMID: 32061922 DOI: 10.1016/j.pharmthera.2020.107502] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
58 Morganti S, Curigliano G. Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. Expert Review of Precision Medicine and Drug Development 2020;5:7-22. [DOI: 10.1080/23808993.2020.1720508] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Osei E, Walters P, Masella O, Tennant Q, Fishwick A, Dadzie E, Bhangu A, Darko J. A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy. J Radiother Pract 2021;20:83-98. [DOI: 10.1017/s1460396919000955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
60 Simpson AD, Soo YWJ, Rieunier G, Aleksic T, Ansorge O, Jones C, Macaulay VM. Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma. Br J Cancer 2020;122:624-9. [PMID: 31857716 DOI: 10.1038/s41416-019-0677-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
61 Chen Z, Jiang X, Feng Y, Li X, Chen D, Mao Z, He D, Zhu Y, Wang H. DECREASE IN ACROMEGALY-ASSOCIATED THYROID ENLARGEMENT AFTER NORMALIZATION OF IGF-1 LEVELS: A PROSPECTIVE OBSERVATION AND IN VITRO STUDY. Endocr Pract 2020;26:369-77. [PMID: 31859554 DOI: 10.4158/EP-2019-0353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway KA, Hornick JL, Flieder DB, Chugh R, Rink L, Van den Abbeele AD. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res 2020;26:1837-45. [PMID: 31792037 DOI: 10.1158/1078-0432.CCR-19-1069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
63 Werner H, Sarfstein R, Bruchim I. Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy. Expert Opin Investig Drugs 2019;28:1101-12. [PMID: 31731883 DOI: 10.1080/13543784.2019.1694660] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
64 Sarfstein R, Nagaraj K, LeRoith D, Werner H. Differential Effects of Insulin and IGF1 Receptors on ERK and AKT Subcellular Distribution in Breast Cancer Cells. Cells 2019;8:E1499. [PMID: 31771180 DOI: 10.3390/cells8121499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
65 Chen JF, Lin PW, Tsai YR, Yang YC, Kang HY. Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy. Cells 2019;8:E1318. [PMID: 31731497 DOI: 10.3390/cells8111318] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
66 Kasprzak A, Adamek A. Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications. Int J Mol Sci 2019;20:E4915. [PMID: 31623387 DOI: 10.3390/ijms20194915] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
67 Neirijnck Y, Papaioannou MD, Nef S. The Insulin/IGF System in Mammalian Sexual Development and Reproduction. Int J Mol Sci 2019;20:E4440. [PMID: 31505893 DOI: 10.3390/ijms20184440] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
68 Vella V, Nicolosi ML, Giuliano M, Morrione A, Malaguarnera R, Belfiore A. Insulin Receptor Isoform A Modulates Metabolic Reprogramming of Breast Cancer Cells in Response to IGF2 and Insulin Stimulation. Cells 2019;8:E1017. [PMID: 31480557 DOI: 10.3390/cells8091017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
69 Russo A, Paret C, Alt F, Burhenne J, Fresnais M, Wagner W, Glaser M, Bender H, Huprich S, Harter PN, Filipski K, Lehmann N, Backes N, Roth L, Seidmann L, Sommer C, Brockmann MA, Pietsch T, Neu MA, Wingerter A, Faber J. Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. Int J Mol Sci 2019;20:E4267. [PMID: 31480400 DOI: 10.3390/ijms20174267] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
70 Aydemirli MD, Corver W, Beuk R, Roepman P, Solleveld-Westerink N, van Wezel T, Kapiteijn E, Morreau H. Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer. Cancers (Basel) 2019;11:E1185. [PMID: 31443247 DOI: 10.3390/cancers11081185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
71 Osher E, Macaulay VM. Therapeutic Targeting of the IGF Axis. Cells 2019;8:E895. [PMID: 31416218 DOI: 10.3390/cells8080895] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
72 Manzella L, Massimino M, Stella S, Tirrò E, Pennisi MS, Martorana F, Motta G, Vitale SR, Puma A, Romano C, Di Gregorio S, Russo M, Malandrino P, Vigneri P. Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment. Int J Mol Sci 2019;20:E3258. [PMID: 31269742 DOI: 10.3390/ijms20133258] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
73 Vewinger N, Huprich S, Seidmann L, Russo A, Alt F, Bender H, Sommer C, Samuel D, Lehmann N, Backes N, Roth L, Harter PN, Filipski K, Faber J, Paret C. IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients. Int J Mol Sci 2019;20:E3027. [PMID: 31234291 DOI: 10.3390/ijms20123027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
74 Selfe J, Shipley JM. IGF signalling in germ cells and testicular germ cell tumours: roles and therapeutic approaches. Andrology 2019;7:536-44. [PMID: 31179642 DOI: 10.1111/andr.12658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
75 De Giovanni C, Landuzzi L, Palladini A, Ianzano ML, Nicoletti G, Ruzzi F, Amici A, Croci S, Nanni P, Lollini PL. Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. Cancers (Basel) 2019;11:E517. [PMID: 30979001 DOI: 10.3390/cancers11040517] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Wang SQ, Yang XY, Yu XF, Cui SX, Qu XJ. Knockdown of IGF-1R Triggers Viral RNA Sensor MDA5- and RIG-I-Mediated Mitochondrial Apoptosis in Colonic Cancer Cells. Mol Ther Nucleic Acids 2019;16:105-17. [PMID: 30861413 DOI: 10.1016/j.omtn.2019.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Choucair A, Pham TH, Omarjee S, Jacquemetton J, Kassem L, Trédan O, Rambaud J, Marangoni E, Corbo L, Treilleux I, Le Romancer M. The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer.Oncogene. 2019;38:4015-4027. [PMID: 30692633 DOI: 10.1038/s41388-019-0694-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
78 Paul MD, Hristova K. The RTK Interactome: Overview and Perspective on RTK Heterointeractions. Chem Rev 2019;119:5881-921. [PMID: 30589534 DOI: 10.1021/acs.chemrev.8b00467] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
79 Samadi P, Afshar S, Amini R, Najafi R, Mahdavinezhad A, Sedighi Pashaki A, Gholami MH, Saidijam M. Let‐7e enhances the radiosensitivity of colorectal cancer cells by directly targeting insulin‐like growth factor 1 receptor. J Cell Physiol 2019;234:10718-25. [DOI: 10.1002/jcp.27742] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
80 Bagheri A, Khorshid HRK, Tavallaie M, Mowla SJ, Sherafatian M, Rashidi M, Zargari M, Boroujeni ME, Hosseini SM. A panel of noncoding RNAs in non-small-cell lung cancer. J Cell Biochem. 2019;120:8280-8290. [PMID: 30485511 DOI: 10.1002/jcb.28111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
81 Khalil A, Jameson MJ. Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro. Horm Cancer 2019;10:11-23. [PMID: 30350263 DOI: 10.1007/s12672-018-0352-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
82 Zabłocka-Słowińska K, Płaczkowska S, Prescha A, Pawełczyk K, Kosacka M, Porębska I, Grajeta H. Systemic redox status in lung cancer patients is related to altered glucose metabolism. PLoS One 2018;13:e0204173. [PMID: 30235348 DOI: 10.1371/journal.pone.0204173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
83 Altieri B, Colao A, Faggiano A. The role of insulin-like growth factor system in the adrenocortical tumors. Minerva Endocrinol 2019;44:43-57. [PMID: 29963827 DOI: 10.23736/S0391-1977.18.02882-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
84 Himes BE, Obraztsova K, Lian L, Shumyatcher M, Rue R, Atochina-Vasserman EN, Hur SK, Bartolomei MS, Evans JF, Krymskaya VP. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells. PLoS One 2018;13:e0197105. [PMID: 29758070 DOI: 10.1371/journal.pone.0197105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
85 Chen Y, Zhong W, Chen B, Yang C, Zhou S, Liu J. Effect of curcumin on vascular endothelial growth factor in hypoxic HepG2 cells via the insulin-like growth factor 1 receptor signaling pathway. Exp Ther Med 2018;15:2922-8. [PMID: 29599831 DOI: 10.3892/etm.2018.5783] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]